Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: Implications for tumor vaccination

Taizo Hoshino, Yin Zheng Jiang, Daniel Dunn, Devchand Paul, Muzaffar Qazilbash, Kenneth Cowan, Jianxiang Wang, John Barrett, Johnson Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Interleukin-12 (IL-12) is a heterodimeric cytokine that is central to the development of T helper 1-dependent cellular immunity. Although this cytokine has potential therapeutic application as an antineoplastic agent, the systemic infusion of IL-12 has led to toxic fatalities; hence, restriction of expression of IL-12 to the microenvironment of target tumor cells has obvious appeal. In this study, we examined whether tumor cells that were liposome-transfected with IL-12 could enhance the induction of cytolytic lymphocyte immunity to the native tumor. The plasmid expression vector that we used has several useful features including replication to high copy number as an episome and a polycistronic message enabling the production of both the p35 and p40 subunits of IL-12 without alternative splicing; up to 3 ng/mL/106/48 hours of IL-12 was produced following transfection. Tumor cells transfected with IL-12 were superior to untransfected cells in the induction of lymphocyte-mediated cytolysis. IL-12 transfectants induced a heterogeneous population of natural killer, lymphokine activated killer, and cytolytic T lymphocytes, the latter of which exhibited tumor-specific activity. Our studies suggest that liposome-mediated transfection of tumor cells with an episomal, high copy number plasmid vector expressing both IL-12 subunits is a promising approach to cancer vaccination, a strategy that could be implemented ex vivo in treating malignancies such as metastatic ovarian cancer.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalCancer Gene Therapy
Volume5
Issue number3
StatePublished - Dec 1 1998

Fingerprint

Interleukin-12
Transfection
Vaccination
Complementary DNA
Neoplasms
Plasmids
Liposomes
Interleukin-12 Subunit p35
Interleukin-12 Subunit p40
Lymphocytes
Cytokines
Tumor Microenvironment
Lymphokines
Poisons
Alternative Splicing
Innate Immunity
Cellular Immunity
Antineoplastic Agents
Ovarian Neoplasms
T-Lymphocytes

Keywords

  • 2008 cells
  • CTL
  • Cytotoxicity
  • Interleukin-12
  • NK cells
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor : Implications for tumor vaccination. / Hoshino, Taizo; Jiang, Yin Zheng; Dunn, Daniel; Paul, Devchand; Qazilbash, Muzaffar; Cowan, Kenneth; Wang, Jianxiang; Barrett, John; Liu, Johnson.

In: Cancer Gene Therapy, Vol. 5, No. 3, 01.12.1998, p. 150-157.

Research output: Contribution to journalArticle

Hoshino, T, Jiang, YZ, Dunn, D, Paul, D, Qazilbash, M, Cowan, K, Wang, J, Barrett, J & Liu, J 1998, 'Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: Implications for tumor vaccination', Cancer Gene Therapy, vol. 5, no. 3, pp. 150-157.
Hoshino, Taizo ; Jiang, Yin Zheng ; Dunn, Daniel ; Paul, Devchand ; Qazilbash, Muzaffar ; Cowan, Kenneth ; Wang, Jianxiang ; Barrett, John ; Liu, Johnson. / Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor : Implications for tumor vaccination. In: Cancer Gene Therapy. 1998 ; Vol. 5, No. 3. pp. 150-157.
@article{e4e84829733c406cb5f1531e9e359df0,
title = "Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: Implications for tumor vaccination",
abstract = "Interleukin-12 (IL-12) is a heterodimeric cytokine that is central to the development of T helper 1-dependent cellular immunity. Although this cytokine has potential therapeutic application as an antineoplastic agent, the systemic infusion of IL-12 has led to toxic fatalities; hence, restriction of expression of IL-12 to the microenvironment of target tumor cells has obvious appeal. In this study, we examined whether tumor cells that were liposome-transfected with IL-12 could enhance the induction of cytolytic lymphocyte immunity to the native tumor. The plasmid expression vector that we used has several useful features including replication to high copy number as an episome and a polycistronic message enabling the production of both the p35 and p40 subunits of IL-12 without alternative splicing; up to 3 ng/mL/106/48 hours of IL-12 was produced following transfection. Tumor cells transfected with IL-12 were superior to untransfected cells in the induction of lymphocyte-mediated cytolysis. IL-12 transfectants induced a heterogeneous population of natural killer, lymphokine activated killer, and cytolytic T lymphocytes, the latter of which exhibited tumor-specific activity. Our studies suggest that liposome-mediated transfection of tumor cells with an episomal, high copy number plasmid vector expressing both IL-12 subunits is a promising approach to cancer vaccination, a strategy that could be implemented ex vivo in treating malignancies such as metastatic ovarian cancer.",
keywords = "2008 cells, CTL, Cytotoxicity, Interleukin-12, NK cells, Tumor immunotherapy",
author = "Taizo Hoshino and Jiang, {Yin Zheng} and Daniel Dunn and Devchand Paul and Muzaffar Qazilbash and Kenneth Cowan and Jianxiang Wang and John Barrett and Johnson Liu",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "5",
pages = "150--157",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor

T2 - Implications for tumor vaccination

AU - Hoshino, Taizo

AU - Jiang, Yin Zheng

AU - Dunn, Daniel

AU - Paul, Devchand

AU - Qazilbash, Muzaffar

AU - Cowan, Kenneth

AU - Wang, Jianxiang

AU - Barrett, John

AU - Liu, Johnson

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Interleukin-12 (IL-12) is a heterodimeric cytokine that is central to the development of T helper 1-dependent cellular immunity. Although this cytokine has potential therapeutic application as an antineoplastic agent, the systemic infusion of IL-12 has led to toxic fatalities; hence, restriction of expression of IL-12 to the microenvironment of target tumor cells has obvious appeal. In this study, we examined whether tumor cells that were liposome-transfected with IL-12 could enhance the induction of cytolytic lymphocyte immunity to the native tumor. The plasmid expression vector that we used has several useful features including replication to high copy number as an episome and a polycistronic message enabling the production of both the p35 and p40 subunits of IL-12 without alternative splicing; up to 3 ng/mL/106/48 hours of IL-12 was produced following transfection. Tumor cells transfected with IL-12 were superior to untransfected cells in the induction of lymphocyte-mediated cytolysis. IL-12 transfectants induced a heterogeneous population of natural killer, lymphokine activated killer, and cytolytic T lymphocytes, the latter of which exhibited tumor-specific activity. Our studies suggest that liposome-mediated transfection of tumor cells with an episomal, high copy number plasmid vector expressing both IL-12 subunits is a promising approach to cancer vaccination, a strategy that could be implemented ex vivo in treating malignancies such as metastatic ovarian cancer.

AB - Interleukin-12 (IL-12) is a heterodimeric cytokine that is central to the development of T helper 1-dependent cellular immunity. Although this cytokine has potential therapeutic application as an antineoplastic agent, the systemic infusion of IL-12 has led to toxic fatalities; hence, restriction of expression of IL-12 to the microenvironment of target tumor cells has obvious appeal. In this study, we examined whether tumor cells that were liposome-transfected with IL-12 could enhance the induction of cytolytic lymphocyte immunity to the native tumor. The plasmid expression vector that we used has several useful features including replication to high copy number as an episome and a polycistronic message enabling the production of both the p35 and p40 subunits of IL-12 without alternative splicing; up to 3 ng/mL/106/48 hours of IL-12 was produced following transfection. Tumor cells transfected with IL-12 were superior to untransfected cells in the induction of lymphocyte-mediated cytolysis. IL-12 transfectants induced a heterogeneous population of natural killer, lymphokine activated killer, and cytolytic T lymphocytes, the latter of which exhibited tumor-specific activity. Our studies suggest that liposome-mediated transfection of tumor cells with an episomal, high copy number plasmid vector expressing both IL-12 subunits is a promising approach to cancer vaccination, a strategy that could be implemented ex vivo in treating malignancies such as metastatic ovarian cancer.

KW - 2008 cells

KW - CTL

KW - Cytotoxicity

KW - Interleukin-12

KW - NK cells

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032067457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032067457&partnerID=8YFLogxK

M3 - Article

C2 - 9622098

AN - SCOPUS:0032067457

VL - 5

SP - 150

EP - 157

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 3

ER -